Development of Vascular Disrupting Agents
Development of Vascular Disrupting Agents
复制标题
DOI：
10.1007/978-1-4419-6609-4_1
复制
发表时间：
2010-01-01
期刊：
影响因子：
--
通讯作者：
Chaplin, David J.
中科院分区：
文献类型：
--
作者：
Dougherty, Graeme J.;Chaplin, David J.
今天使用的大多数癌症疗法都是针对恶性细胞群体的。从广义上讲，特异性是通过利用正常细胞和肿瘤细胞在各种关键过程中的内在差异来实现的，这些过程包括增殖活性、DNA修复和对凋亡刺激的反应。尽管继续取得进展，但单靠化疗很少能治愈。因此，近年来，人们的兴趣越来越多地集中在替代策略上，这些策略转而针对肿瘤生存和生长所依赖的各种正常细胞类型。在这一章中，我们将探讨导致血管破坏疗法发展的历史事件，并讨论目前用于选择性破坏实体肿瘤新生血管的主要方法。
The majority of the cancer therapies in use today target the malignant cell population. In broad terms, specificity is achieved by exploiting intrinsic differences between normal cells and tumor cells with respect to various key processes including proliferative activity, DNA repair and responsiveness to apoptotic stimuli. Although progress continues to be made, it remains the case that chemotherapy alone is rarely curative. Thus, in recent years increased interest has focused on alternative strategies that instead target various normal cell types upon which the survival and growth of a tumor depends. In this chapter we explore the historical events that lead to development of vascular disrupting therapies and discuss the major approaches currently employed to selectively destroy the neovasculature of solid tumors.